Acta Haematol. 2001;105(3):130-6.

Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside.

Source

Roger Williams Cancer Center, Providence, RI 02908, USA. lawrenceglum@cs.com

Abstract

Nontoxic approaches are needed to improve overall survival (OS) and progression-free survival (PFS) for high-risk breast cancer. Combination immunotherapy (IT) consisting of activated T cells (ATC), interleukin-2 (IL-2), and CTL (GM-CSF) was given after peripheral blood stem cell transplant (PBSCT). There were no major toxicities and there appear to be improvements in OS and PFS over historical controls. In order to develop specific cytotoxic T lymphocytes (CTL), we combined ATC with the use of bispecific antibody (BiAb). By arming ATC with anti-CD3 x anti-HER2/neu BiAb (HER2BiAb), the approach converts nonspecific ATC into HER2/neu (HER2) specific CTL. ATC remain armed, kill tumor targets for days, and produce cytokines after binding to tumor. Arming ATC with BiAbs may prove to be effective for targeting a variety of tumors with and without high-dose chemotherapy.

PMID:: 11463985; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Icon for S. Karger AG, Basel, Switzerland

Save items

Related citations in PubMed

Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. [J Hematother Stem Cell Res. 2001]
Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG. J Hematother Stem Cell Res. 2001 Apr; 10(2):247-60.
Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas. [Anticancer Res. 2005]
Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
Lum HE, Miller M, Davol PA, Grabert RC, Davis JB, Lum LG. Anticancer Res. 2005 Jan-Feb; 25(1A):43-52.
Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. [Clin Cancer Res. 2006]
Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG. Clin Cancer Res. 2006 Jan 15; 12(2):569-76.
Review G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). [J Hematother. 1995]
Review G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R, Valerius T, Wieland G, Becker W, Steininger H, Deo Y, Helm G, Gramatzki M, Van de Winkel JG, Lang N. J Hematother. 1995 Oct; 4(5):415-21.
Review Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. [Leuk Lymphoma. 1995]
Review Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA. Leuk Lymphoma. 1995 Nov; 19(5-6):381-93.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Activated T-cell and bispecific antibody immunotherapy for high-risk breast canc...
Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside.
Acta Haematol. 2001 ;105(3):130-6.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: